Citius Pharmaceuticals (CTXR) Revenue (2025 - 2026)

Citius Pharmaceuticals' (CTXR) quarterly Revenue came in at $1.5 million in Q2 2026, down 10.41% quarter-over-quarter from $1.7 million in Q1 2026.

Analysis

Citius Pharmaceuticals (CTXR) Revenue (2025 - 2026) Analysis & Trends

Citius Pharmaceuticals (CTXR) has reported Revenue for 2 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Johnson & Johnson	663.08 Bn	642.33 Bn	17.26 Bn	25.31 Bn
2	AbbVie	453.04 Bn	446.51 Bn	12.70 Bn	16.99 Bn
3	Merck	370.87 Bn	363.78 Bn	12.21 Bn	16.61 Bn
4	Novartis Ag	305.29 Bn	298.00 Bn	11.24 Bn	14.41 Bn
5	Pfizer	162.10 Bn	150.70 Bn	10.94 Bn	15.03 Bn
6	Sanofi	53.95 Bn	46.98 Bn	10.79 Bn	13.48 Bn
7	Revolution Medicines	45.00 Bn	45.00 Bn	-	-
8	Incyte	25.47 Bn	20.94 Bn	1.57 Bn	1.67 Bn
9	United Therapeutics	20.81 Bn	18.15 Bn	683.80 Mn	783.30 Mn
10	Citius Pharmaceuticals	16.20 Mn	25.49 Mn	1.00 Mn	1.49 Mn

Historic Data

Download Data